This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Acorda Therapeutics, Inc.
Drug Names(s): AC105
Description: AC105 is a proprietary magnesium formulation within a polyethylene glycol (PEG). In preclinical studies, AC105 demonstrated neuroprotective properties and improvement of locomotor function in SCI and cognitive function in TBI when therapy was initiated within four hours of injury.
The potential neuroprotective mechanisms of magnesium include the attenuation of excitotoxicity by NMDA receptor blockade, the reduction in free radical generation and glutamate release by membrane stabilization, the antagonism of intracellular calcium through the IP-3 messenger system, and the reduction in apoptosis and expression of p53-related proteins.
Deal Structure: In July 2011, Acorda licensed worldwide development and commercialization rights AC105 from Medtronic. Acorda made a $3 million upfront payment to Medtronic and will make up to $32 million in regulatory and development milestone payments. A single-digit sales royalty will also be paid by Acorda to Medtronic if AC105 is commercialized by Acorda. Acorda's development and commercialization rights are exclusive in all fields (including SCI, TBI and stroke) for certain formulations of the licensed compound. For other formulations, Acorda's rights are exclusive for indications of interest to Acorda, including SCI, TBI, stroke and all other traumatic and ischemic central nervous system indications, while Medtronic has non-exclusive (with Acorda) development rights in specific areas, including certain areas of pain and musculoskeletal indications.
Additional information available to subscribers only: